TABLE 1.
Baseline Patient Demographics and Characteristics
| Characteristic | Spartalizumab 400 mg Every 4 Weeks (N = 42) |
|---|---|
| Central pathology review | |
| ATC | 38 (90.5) |
| Other | 2 (4.8) |
| Missing | 2 (4.8) |
| Age, years, median (range) | 62.5 (46–83) |
| Sex, male | 23 (54.8) |
| ECOG PS | |
| 0 | 17 (40.5) |
| 1 | 25 (59.5) |
| Prior treatment regimens | |
| 0 | 17 (40.5) |
| 1 | 20 (47.6) |
| ≥ 2 | 5 (11.9) |
| Prior radiation | |
| Yes | 30 (71.4) |
| Prior thyroidectomy and/or neck dissection | |
| Yes | 28 (66.7) |
| Metastatic sites at study entry | |
| Lung | 35 (83.3) |
| Lymph node | 20 (47.6) |
| Bone | 5 (11.9) |
| Liver | 3 (7.1) |
| BRAF V600 mutation by Cobas 4800 | |
| Mutant | 12 (28.6) |
| Nonmutant | 26 (61.9) |
| Missing | 4 (9.5) |
NOTE. Data are presented as No. (%) unless otherwise noted.
Abbreviations: ATC, anaplastic thyroid carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status.